Patents by Inventor Rena May

Rena May has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WT1 HLA class II-binding peptides and compositions and methods comprising same
    Patent number: 12528849
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: January 20, 2026
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Scheinberg, Javier Pinilla-Ibarz, Rena May
  • Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer
    Publication number: 20230406931
    Abstract: The disclosure generally relates to methods for treating cancer in a patient using durvalumab in combination with chemotherapy based on the patient's minimal residual status. Specifically, the disclosure relates to preventing or treating a recurrent tumor in a patient, wherein the patient is minimal residual disease-positive (MRD+), using durvalumab and chemotherapy.
    Type: Application
    Filed: October 11, 2021
    Publication date: December 21, 2023
    Inventors: Phillip DENNIS, Lynne POOLE, Rena MAY
  • IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20230265122
    Abstract: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: July 21, 2022
    Publication date: August 24, 2023
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David SCHEINBERG, RENA MAY
  • Single wall nanotube constructs and uses thereof
    Patent number: 11564988
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: January 31, 2023
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • WT1 HLA class II-binding peptides and compositions and methods comprising same
    Patent number: 11548924
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: January 10, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: David Scheinberg, Javier Pinilla-Ibarz, Rena May
  • WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME
    Publication number: 20220380423
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 1, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David SCHEINBERG, Javier Pinilla-Ibarz, Rena May
  • Immunogenic WT-1 peptides and methods of use thereof
    Patent number: 11414457
    Abstract: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 16, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Scheinberg, Rena May
  • Single Wall Nanotube Constructs and Uses Thereof
    Publication number: 20200061196
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Application
    Filed: September 9, 2019
    Publication date: February 27, 2020
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME
    Publication number: 20190322713
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: February 7, 2019
    Publication date: October 24, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: DAVID SCHEINBERG, Javier Pinilla-Ibarz, Rena May
  • Single wall nanotube constructs and uses thereof
    Patent number: 10406236
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: September 10, 2019
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190270776
    Abstract: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 5, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Scheinberg, Rena May
  • WT1 HLA class II-binding peptides and compositions and methods comprising same
    Patent number: 10221224
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: March 5, 2019
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
  • Single Wall Nanotube Constructs and Uses Thereof
    Publication number: 20170297912
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Application
    Filed: April 24, 2017
    Publication date: October 19, 2017
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • Single wall nanotube constructs and uses thereof
    Patent number: 9629927
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: April 25, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20160368948
    Abstract: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: January 14, 2016
    Publication date: December 22, 2016
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David A. Scheinberg, Rena May
  • WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME
    Publication number: 20160264638
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: January 8, 2016
    Publication date: September 15, 2016
    Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
  • Immunogenic WT-1 peptides and methods of use thereof
    Patent number: 9265816
    Abstract: This invention provides mutated WT1 peptides SGQAYMFPNAPYLPSCLES (SEQ ID No:41) and QAYMFPNAPYLPSCL (SEQ ID No:42), immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: February 23, 2016
    Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David A. Scheinberg, Rena May
  • WT1 HLA class II—binding peptides and compositions and methods comprising same
    Patent number: 9233149
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: January 12, 2016
    Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
  • WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME
    Publication number: 20140220054
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 7, 2014
    Inventors: David A. SCHEINBERG, Javier Pinilla-Ibarz, Rena May
  • WT1 HLA class II-binding peptides and compositions and methods comprising same
    Patent number: 8765687
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: July 1, 2014
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May